HRP20201315T1 - Pripravak koji sadrži hidrokortizon - Google Patents

Pripravak koji sadrži hidrokortizon Download PDF

Info

Publication number
HRP20201315T1
HRP20201315T1 HRP20201315TT HRP20201315T HRP20201315T1 HR P20201315 T1 HRP20201315 T1 HR P20201315T1 HR P20201315T T HRP20201315T T HR P20201315TT HR P20201315 T HRP20201315 T HR P20201315T HR P20201315 T1 HRP20201315 T1 HR P20201315T1
Authority
HR
Croatia
Prior art keywords
preparation
amount
hydroxypropylmethylcellulose
hydrocortisone
sealing layer
Prior art date
Application number
HRP20201315TT
Other languages
English (en)
Croatian (hr)
Inventor
Hiep Huatan
Richard Ross
Martin Whitaker
Norbert Poellinger
Annette Grave
Original Assignee
Diurnal Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diurnal Limited filed Critical Diurnal Limited
Publication of HRP20201315T1 publication Critical patent/HRP20201315T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20201315TT 2013-05-17 2014-05-12 Pripravak koji sadrži hidrokortizon HRP20201315T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1308933.9A GB201308933D0 (en) 2013-05-17 2013-05-17 Paediatric composition
EP14727028.4A EP2978414B1 (en) 2013-05-17 2014-05-12 Composition comprising hydrocortisone
PCT/GB2014/051442 WO2014184525A1 (en) 2013-05-17 2014-05-12 Composition comprising hydrocortisone

Publications (1)

Publication Number Publication Date
HRP20201315T1 true HRP20201315T1 (hr) 2020-11-27

Family

ID=48746932

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201315TT HRP20201315T1 (hr) 2013-05-17 2014-05-12 Pripravak koji sadrži hidrokortizon

Country Status (25)

Country Link
US (1) US9649280B2 (OSRAM)
EP (1) EP2978414B1 (OSRAM)
JP (1) JP6371379B2 (OSRAM)
KR (1) KR102219919B1 (OSRAM)
CN (1) CN105120848B (OSRAM)
AU (1) AU2014267041B2 (OSRAM)
BR (1) BR112015028025B1 (OSRAM)
CA (1) CA2909060C (OSRAM)
CY (1) CY1123284T1 (OSRAM)
DK (1) DK2978414T3 (OSRAM)
ES (1) ES2813382T3 (OSRAM)
GB (2) GB201308933D0 (OSRAM)
HR (1) HRP20201315T1 (OSRAM)
HU (1) HUE050917T2 (OSRAM)
IL (1) IL242275B (OSRAM)
LT (1) LT2978414T (OSRAM)
MX (1) MX379168B (OSRAM)
PL (1) PL2978414T3 (OSRAM)
PT (1) PT2978414T (OSRAM)
RS (1) RS60734B1 (OSRAM)
RU (1) RU2664678C2 (OSRAM)
SI (1) SI2978414T1 (OSRAM)
SM (1) SMT202000473T1 (OSRAM)
WO (1) WO2014184525A1 (OSRAM)
ZA (1) ZA201507210B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
US20190180872A1 (en) * 2017-12-12 2019-06-13 International Business Machines Corporation Second Opinion Decision Support Using Patient Electronic Medical Records
WO2025144994A1 (en) * 2023-12-29 2025-07-03 Regents Of The University Of Minnesota Compositions and methods for intranasal delivery of hydrocortisone
WO2025240605A1 (en) 2024-05-15 2025-11-20 Neurocrine Biosciences, Inc. Combination treatment

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE102022T1 (de) 1990-08-30 1994-03-15 Senju Pharma Co Zusammensetzung zur kontrollierten abgabe von medikamenten.
DK0876142T3 (da) 1996-01-16 2001-11-19 Advanced Polymer Systems Inc Topisk tilførsel af lægemidler til den nedre mavetarmkanal
KR20040016202A (ko) * 2002-08-16 2004-02-21 주식회사 제이알팜 쓴맛이 차폐된 히드로코르티손 경구용 약제 조성물 및 그제조방법
NZ551336A (en) 2004-04-22 2010-04-30 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
CA2579767A1 (en) * 2004-04-30 2005-11-10 Astellas Pharma Inc. Oral pharmaceutical composition in timed-release particle form and fast-disintegrating tablets containing this composition
PT1765404E (pt) * 2004-05-31 2009-03-31 Almirall Lab Combinações compreendendo agentes antimuscarínicos e agonistas beta-adrenérgicos
WO2006026504A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Mucoadhesive oral formulations of high permeability, high solubility drugs
RU2290940C2 (ru) * 2004-10-18 2007-01-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская Государственная Медицинская академия" МЗ РФ (ГОУ ВПО НижГМА) Средство для коррекции острой почечной недостаточности при токсическом гепаторенальном синдроме, индуцированном четыреххлористым углеродом, и способ коррекции острой почечной недостаточности при токсическом гепаторенальном синдроме, индуцированном четыреххлористым углеродом
EP1901728A2 (en) * 2005-06-03 2008-03-26 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
WO2008126076A2 (en) * 2007-04-11 2008-10-23 Perrigo Israel Pharmaceuticals Ltd. Low-dose mometasone formulations
GB0817120D0 (en) 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
CN102448464A (zh) 2009-04-07 2012-05-09 杜奥科特药物公司 改进的糖皮质激素疗法
EP3403654B1 (en) * 2009-10-01 2019-07-31 Adare Development I, L.P. Orally administered corticosteroid compositions
CN102958515A (zh) * 2009-12-02 2013-03-06 阿普塔利斯制药有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
JP2013526552A (ja) 2010-05-20 2013-06-24 デュオコート・ファーマ・アクチボラゲット グルココルチコイドベース組成物の薬量学および新規な投与方法
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition

Also Published As

Publication number Publication date
DK2978414T3 (da) 2020-08-24
US20160081942A1 (en) 2016-03-24
HK1214131A1 (zh) 2016-07-22
RU2015150303A3 (OSRAM) 2018-03-26
AU2014267041B2 (en) 2018-11-22
GB201308933D0 (en) 2013-07-03
GB201516973D0 (en) 2015-11-11
MX379168B (es) 2025-03-10
HUE050917T2 (hu) 2021-01-28
CN105120848B (zh) 2019-06-04
RU2664678C2 (ru) 2018-08-21
SMT202000473T1 (it) 2020-11-10
SI2978414T1 (sl) 2020-10-30
GB2527233A (en) 2015-12-16
PT2978414T (pt) 2020-08-27
WO2014184525A1 (en) 2014-11-20
BR112015028025A2 (pt) 2017-07-25
CY1123284T1 (el) 2021-12-31
CA2909060C (en) 2020-03-10
CN105120848A (zh) 2015-12-02
KR20160011205A (ko) 2016-01-29
CA2909060A1 (en) 2014-11-20
JP2016518439A (ja) 2016-06-23
PL2978414T3 (pl) 2020-11-16
KR102219919B1 (ko) 2021-02-25
LT2978414T (lt) 2020-09-25
AU2014267041A1 (en) 2015-10-15
ZA201507210B (en) 2017-07-26
IL242275B (en) 2018-08-30
MX2015015759A (es) 2016-03-15
RS60734B1 (sr) 2020-09-30
EP2978414A1 (en) 2016-02-03
JP6371379B2 (ja) 2018-08-08
ES2813382T3 (es) 2021-03-23
US9649280B2 (en) 2017-05-16
EP2978414B1 (en) 2020-07-22
RU2015150303A (ru) 2017-06-22
GB2527233B (en) 2017-07-05
BR112015028025A8 (pt) 2019-12-31
NZ712756A (en) 2020-12-18
BR112015028025B1 (pt) 2022-11-29

Similar Documents

Publication Publication Date Title
HRP20201315T1 (hr) Pripravak koji sadrži hidrokortizon
JP2014111603A5 (OSRAM)
JP2017226708A5 (OSRAM)
BR112014027942A2 (pt) dispersão de pó pró-lipossomal; composição farmacêutica; forma de dosagem oral; e método para tratar um indivíduo que necessite de terapia de testosterona
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
GEP20166457B (en) Low-oil pharmaceutical emulsion compositions comprising progestogen
MX357551B (es) Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
HRP20201627T1 (hr) Postupak liječenja s tradipitantom
HRP20221327T1 (hr) Niraparib, abirateron acetat i prednizon za liječenje raka prostate
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
MX380070B (es) Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina.
BR112015018895A2 (pt) composição farmacêutica multiparticulada compreendendo uma multiplicidade de dois tipos de pelotas
HRP20200452T1 (hr) Liječenje insuficijencije nadbubrežne žlijezde
JP2016518439A5 (OSRAM)
PL408608A1 (pl) Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
HRP20191491T1 (hr) Biotin za liječenje demijelinizirajućih neuropatija
WO2016178510A3 (ko) 진세노사이드 F1 또는 Rg3를 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
PH12016501756B1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
RU2017112748A (ru) Композиции онапристона пролонгированного действия и способы
GB202004346D0 (en) Preparation procedure for panax notoginseng medicinal liquor for oral administration for treating rheumatic ostalgia
EP4474012A3 (en) Melatonin mini-tablets and method of manufacturing the same
WO2016175589A3 (ko) 혼합 생약 추출물을 함유하는 호흡기 질환 예방 또는 치료용 약학적 조성물
MX2016016021A (es) Composicion farmaceutica para prevenir y tratar la demencia senil y su metodo de preparacion.
MX387263B (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma.